Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer.

Thorek DLJ, Ku AT, Mitsiades N, Veach D, Watson PA, Metha D, Strand SE, Sharma SK, Lewis JS, Abou DS, Lilja HG, Larson SM, McDevitt MR, Ulmert D.

Clin Cancer Res. 2019 Jan 15;25(2):881-891. doi: 10.1158/1078-0432.CCR-18-1521. Epub 2018 Sep 25.

2.

Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer.

McDevitt MR, Thorek DLJ, Hashimoto T, Gondo T, Veach DR, Sharma SK, Kalidindi TM, Abou DS, Watson PA, Beattie BJ, Timmermand OV, Strand SE, Lewis JS, Scardino PT, Scher HI, Lilja H, Larson SM, Ulmert D.

Nat Commun. 2018 Apr 24;9(1):1629. doi: 10.1038/s41467-018-04107-w.

3.

ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts.

Cheal SM, Ruan S, Veach DR, Longo VA, Punzalan BJ, Wu J, Fung EK, Kelly MP, Kirshner JR, Giurleo JT, Ehrlich G, Han AQ, Thurston G, Olson WC, Zanzonico PB, Larson SM, Carrasquillo JA.

Mol Pharm. 2018 Jun 4;15(6):2133-2141. doi: 10.1021/acs.molpharmaceut.7b01133. Epub 2018 Apr 30.

PMID:
29684277
4.

Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer.

Fox JJ, Gavane SC, Blanc-Autran E, Nehmeh S, Gönen M, Beattie B, Vargas HA, Schöder H, Humm JL, Fine SW, Lewis JS, Solomon SB, Osborne JR, Veach D, Sawyers CL, Weber WA, Scher HI, Morris MJ, Larson SM.

JAMA Oncol. 2018 Feb 1;4(2):217-224. doi: 10.1001/jamaoncol.2017.3588.

5.

In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME).

Pankov D, Sjöström L, Kalidindi T, Lee SG, Sjöström K, Gardner R, McDevitt MR, O'Reilly R, Thorek DLJ, Larson SM, Veach D, Ulmert D.

Oncotarget. 2017 Jul 26;8(39):65917-65931. doi: 10.18632/oncotarget.19579. eCollection 2017 Sep 12.

6.

Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor.

Bosbach B, Rossi F, Yozgat Y, Loo J, Zhang JQ, Berrozpe G, Warpinski K, Ehlers I, Veach D, Kwok A, Manova K, Antonescu CR, DeMatteo RP, Besmer P.

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):E8448-E8457. doi: 10.1073/pnas.1711449114. Epub 2017 Sep 18.

7.

Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis.

Thorek DL, Watson PA, Lee SG, Ku AT, Bournazos S, Braun K, Kim K, Sjöström K, Doran MG, Lamminmäki U, Santos E, Veach D, Turkekul M, Casey E, Lewis JS, Abou DS, van Voss MR, Scardino PT, Strand SE, Alpaugh ML, Scher HI, Lilja H, Larson SM, Ulmert D.

Sci Transl Med. 2016 Nov 30;8(367):367ra167.

8.

Remodeling the Vascular Microenvironment of Glioblastoma with α-Particles.

Behling K, Maguire WF, Di Gialleonardo V, Heeb LE, Hassan IF, Veach DR, Keshari KR, Gutin PH, Scheinberg DA, McDevitt MR.

J Nucl Med. 2016 Nov;57(11):1771-1777. Epub 2016 Jun 3.

9.

Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging.

Pandit-Taskar N, Veach DR, Fox JJ, Scher HI, Morris MJ, Larson SM.

J Nucl Med. 2016 Oct;57(Suppl 3):73S-78S.

10.

Anti-platelet and anti-thrombogenic effects of shikimic acid in sedentary population.

Veach D, Hosking H, Thompson K, Santhakumar AB.

Food Funct. 2016 Aug 10;7(8):3609-16. doi: 10.1039/c6fo00927a. Epub 2016 Aug 2.

PMID:
27480079
11.

Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling.

Fung EK, Cheal SM, Fareedy SB, Punzalan B, Beylergil V, Amir J, Chalasani S, Weber WA, Spratt DE, Veach DR, Bander NH, Larson SM, Zanzonico PB, Osborne JR.

EJNMMI Res. 2016 Dec;6(1):7. doi: 10.1186/s13550-016-0164-0. Epub 2016 Jan 22.

12.

Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor.

Kim TS, Cavnar MJ, Cohen NA, Sorenson EC, Greer JB, Seifert AM, Crawley MH, Green BL, Popow R, Pillarsetty N, Veach DR, Ku AT, Rossi F, Besmer P, Antonescu CR, Zeng S, Dematteo RP.

Clin Cancer Res. 2014 May 1;20(9):2350-62. doi: 10.1158/1078-0432.CCR-13-3033. Epub 2014 Feb 28.

13.

Fluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model.

Benezra M, Hambardzumyan D, Penate-Medina O, Veach DR, Pillarsetty N, Smith-Jones P, Phillips E, Ozawa T, Zanzonico PB, Longo V, Holland EC, Larson SM, Bradbury MS.

Neoplasia. 2012 Dec;14(12):1132-43.

14.

Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor.

Bosbach B, Deshpande S, Rossi F, Shieh JH, Sommer G, de Stanchina E, Veach DR, Scandura JM, Manova-Todorova K, Moore MA, Antonescu CR, Besmer P.

Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):E2276-83. doi: 10.1073/pnas.1115240109. Epub 2012 May 31.

15.

Dosimetry of 18F-labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging.

Dunphy MP, Zanzonico P, Veach D, Somwar R, Pillarsetty N, Lewis J, Larson S.

Mol Imaging Biol. 2012 Feb;14(1):25-31. doi: 10.1007/s11307-010-0462-2.

16.

A magnetic bead-based protein kinase assay with dual detection techniques.

Zhou G, Sylvester JE, Wu D, Veach DR, Kron SJ.

Anal Biochem. 2011 Jan 1;408(1):5-11. doi: 10.1016/j.ab.2010.08.034. Epub 2010 Aug 31.

17.

Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib.

Rossi F, Yozgat Y, de Stanchina E, Veach D, Clarkson B, Manova K, Giancotti FG, Antonescu CR, Besmer P.

Mol Cancer Res. 2010 Sep;8(9):1271-83. doi: 10.1158/1541-7786.MCR-10-0065. Epub 2010 Aug 24.

18.

Cell treatment and lysis in 96-well filter-bottom plates for screening Bcr-Abl activity and inhibition in whole-cell extracts.

Mand MR, Wu D, Veach DR, Kron SJ.

J Biomol Screen. 2010 Apr;15(4):434-40. doi: 10.1177/1087057110363307. Epub 2010 Mar 17.

19.

(124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo.

Doubrovin M, Kochetkova T, Santos E, Veach DR, Smith-Jones P, Pillarsetty N, Balatoni J, Bornmann W, Gelovani J, Larson SM.

J Nucl Med. 2010 Jan;51(1):121-9. doi: 10.2967/jnumed.109.066126.

20.

Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors.

Antczak C, Veach DR, Ramirez CN, Minchenko MA, Shum D, Calder PA, Frattini MG, Clarkson B, Djaballah H.

Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6. doi: 10.1016/j.bmcl.2009.10.085. Epub 2009 Oct 23.

21.

Giving birth to empathy: the effects of similar experience on empathic accuracy, empathic concern, and perceived empathy.

Hodges SD, Kiel KJ, Kramer AD, Veach D, Villanueva BR.

Pers Soc Psychol Bull. 2010 Mar;36(3):398-409. doi: 10.1177/0146167209350326. Epub 2009 Oct 29.

PMID:
19875825
22.

Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance.

Guo T, Hajdu M, Agaram NP, Shinoda H, Veach D, Clarkson BD, Maki RG, Singer S, Dematteo RP, Besmer P, Antonescu CR.

Clin Cancer Res. 2009 Nov 15;15(22):6862-70. doi: 10.1158/1078-0432.CCR-09-1315. Epub 2009 Oct 27.

23.

A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates.

Wu D, Mand MR, Veach DR, Parker LL, Clarkson B, Kron SJ.

Anal Biochem. 2008 Apr 1;375(1):18-26. doi: 10.1016/j.ab.2007.12.023. Epub 2007 Dec 25.

24.

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.

Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, Bromberg JF.

J Clin Invest. 2007 Dec;117(12):3846-56.

25.

Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.

Veach DR, Namavari M, Pillarsetty N, Santos EB, Beresten-Kochetkov T, Lambek C, Punzalan BJ, Antczak C, Smith-Jones PM, Djaballah H, Clarkson B, Larson SM.

J Med Chem. 2007 Nov 15;50(23):5853-7. Epub 2007 Oct 23.

PMID:
17956080
26.

Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.

Guo T, Agaram NP, Wong GC, Hom G, D'Adamo D, Maki RG, Schwartz GK, Veach D, Clarkson BD, Singer S, DeMatteo RP, Besmer P, Antonescu CR.

Clin Cancer Res. 2007 Aug 15;13(16):4874-81.

27.

L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.

Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP, Besmer P, Jungbluth A, Gimbel M, Chen CT, Veach D, Clarkson BD, Paty PB, Weiser MR.

Int J Cancer. 2007 Jul 15;121(2):257-64.

28.

Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells.

Liang X, Hajivandi M, Veach D, Wisniewski D, Clarkson B, Resh MD, Pope RM.

Proteomics. 2006 Aug;6(16):4554-64.

PMID:
16858728
29.

Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.

Azam M, Nardi V, Shakespeare WC, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Sliz P, Veach DR, Bornmann WG, Clarkson B, Dalgarno DC, Sawyer TK, Daley GQ.

Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9244-9. Epub 2006 Jun 5.

30.

Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.

Wendel HG, de Stanchina E, Cepero E, Ray S, Emig M, Fridman JS, Veach DR, Bornmann WG, Clarkson B, McCombie WR, Kogan SC, Hochhaus A, Lowe SW.

Proc Natl Acad Sci U S A. 2006 May 9;103(19):7444-9. Epub 2006 May 1.

31.

Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases.

Reeves PM, Bommarius B, Lebeis S, McNulty S, Christensen J, Swimm A, Chahroudi A, Chavan R, Feinberg MB, Veach D, Bornmann W, Sherman M, Kalman D.

Nat Med. 2005 Jul;11(7):731-9. Epub 2005 Jun 26. Erratum in: Nat Med. 2005 Dec;11(12):1361.

PMID:
15980865
32.

Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors.

Veach DR, Namavari M, Beresten T, Balatoni J, Minchenko M, Djaballah H, Finn RD, Clarkson B, Gelovani JG, Bornmann WG, Larson SM.

Nucl Med Biol. 2005 May;32(4):313-21.

PMID:
15878500
33.

DNA photocleavage and biological activity of a pyrene dihydrodioxin.

Mack ET, Birzniece D, Veach DR, Coyle W, Wilson RM.

Bioorg Med Chem Lett. 2005 Apr 15;15(8):2173-6.

PMID:
15808491
34.

PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.

Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL Jr.

Blood. 2005 May 15;105(10):3995-4003. Epub 2005 Jan 18.

35.

A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.

von Bubnoff N, Veach DR, van der Kuip H, Aulitzky WE, Sänger J, Seipel P, Bornmann WG, Peschel C, Clarkson B, Duyster J.

Blood. 2005 Feb 15;105(4):1652-9. Epub 2004 Sep 30.

36.

Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation.

Deng X, Hofmann ER, Villanueva A, Hobert O, Capodieci P, Veach DR, Yin X, Campodonico L, Glekas A, Cordon-Cardo C, Clarkson B, Bornmann WG, Fuks Z, Hengartner MO, Kolesnick R.

Nat Genet. 2004 Aug;36(8):906-12. Epub 2004 Jul 25.

PMID:
15273685
37.

Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.

Tipping AJ, Baluch S, Barnes DJ, Veach DR, Clarkson BM, Bornmann WG, Mahon FX, Goldman JM, Melo JV.

Leukemia. 2004 Aug;18(8):1352-6.

PMID:
15201856
38.

Enteropathogenic Escherichia coli use redundant tyrosine kinases to form actin pedestals.

Swimm A, Bommarius B, Li Y, Cheng D, Reeves P, Sherman M, Veach D, Bornmann W, Kalman D.

Mol Biol Cell. 2004 Aug;15(8):3520-9. Epub 2004 May 21.

39.
40.

Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.

von Bubnoff N, Veach DR, Miller WT, Li W, Sänger J, Peschel C, Bornmann WG, Clarkson B, Duyster J.

Cancer Res. 2003 Oct 1;63(19):6395-404.

41.

The Arkansas River Valley Rural Health Cooperative: building a three-pronged approach to improved health and health care.

Stewart MK, Redford R, Poe K, Veach D, Hines R, Beachler M.

J Rural Health. 2003;19 Suppl:384-90.

PMID:
14526522
42.

Gleevec inhibits beta-amyloid production but not Notch cleavage.

Netzer WJ, Dou F, Cai D, Veach D, Jean S, Li Y, Bornmann WG, Clarkson B, Xu H, Greengard P.

Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12444-9. Epub 2003 Oct 1.

43.

Two distinct phosphorylation pathways have additive effects on Abl family kinase activation.

Tanis KQ, Veach D, Duewel HS, Bornmann WG, Koleske AJ.

Mol Cell Biol. 2003 Jun;23(11):3884-96.

44.

Structural basis for the autoinhibition of c-Abl tyrosine kinase.

Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, Clarkson B, Superti-Furga G, Kuriyan J.

Cell. 2003 Mar 21;112(6):859-71.

45.

Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.

Wisniewski D, Lambek CL, Liu C, Strife A, Veach DR, Nagar B, Young MA, Schindler T, Bornmann WG, Bertino JR, Kuriyan J, Clarkson B.

Cancer Res. 2002 Aug 1;62(15):4244-55.

46.

Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).

Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J.

Cancer Res. 2002 Aug 1;62(15):4236-43.

47.

Fluorescent monitoring of kinase activity in real time: development of a robust fluorescence-based assay for Abl tyrosine kinase activity.

Hofmann RM, Cotton GJ, Chang EJ, Vidal E, Veach D, Bornmann W, Muir TW.

Bioorg Med Chem Lett. 2001 Dec 17;11(24):3091-4.

PMID:
11720849

Supplemental Content

Support Center